BioLineRx in deal with Univ. of Illinois

Financial terms of the deal, the company's first with a US university, were not disclosed.

BioLineRx Ltd. and the University of Illinois at Urbana-Champaign said Sunday they reached an exclusive worldwide licensing agreement for the research, development and commercialization of BL-4030, an apoptosis agent to treat cancer. Financial terms of the deal, the company's first with a US university, were not disclosed.